Scarica l'app Stockscreener
8.65
2.15%
-0.19
Dopo l'orario di chiusura:
8.52
-0.13
-1.50%
Precedente Chiudi:
$8.84
Aprire:
$8.91
Volume 24 ore:
1.28M
Relative Volume:
0.83
Capitalizzazione di mercato:
$764.05M
Reddito:
$67.48M
Utile/perdita netta:
$-278.67M
Rapporto P/E:
-2.7224
EPS:
-3.1774
Flusso di cassa netto:
$-70.70M
1 W Prestazione:
-3.46%
1M Prestazione:
+4.09%
6M Prestazione:
+5.62%
1 anno Prestazione:
+18.82%
Intervallo 1D:
$8.535
$9.00
Intervallo di 1 settimana:
$8.535
$9.60
Portata 52W:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.65 | 764.05M | 67.48M | -278.67M | -70.70M | -3.1774 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - Yahoo Finance
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales - AlphaStreet
Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
To recruit 4 new staff, Kura Oncology offers 44,700 stock options - Stock Titan
Kura Oncology Q4 Earnings Call Highlights - MarketBeat
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... By GuruFocus - Investing.com Canada
Wedbush Cuts Kura Oncology Price Target to $36 From $38, Outperform Rating Maintained - marketscreener.com
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZI - GuruFocus
Kura Oncology (KURA) Reports Strong Q4 2025 with KOMZIFTI Launch - GuruFocus
Kura Oncology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss - MarketBeat
Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Earnings call transcript: Kura Oncology Q4 2025 sees significant earnings miss, stock dips - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kura Oncology Reports Q4 Earnings Miss - National Today
Kura Oncology 10-K: $67.5M revenue; R&D $251.1M, SG&A $120.0M - TradingView
Kura Oncology: Q4 Earnings Snapshot - KVUE
Kura Oncology: Fourth Quarter Financial Results Overview - Bitget
Kura Oncology (KURA) Faces Mixed Financial Results Amid Promisin - GuruFocus
Earnings Flash (KURA) Kura Oncology Posts Q4 Loss $0.92 a Share, vs. FactSet Est of $0.64 Loss - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q4 2025 Earnings - Quiver Quantitative
Kura Oncology Inc. Q4 Loss Increases - Nasdaq
Kura Oncology Reports Early Commercial Success for KOMZIFTI™ (ziftomenib) with Strong Initial Revenue and Payer Support - Quiver Quantitative
Kura Oncology Q4 Earnings Summary & Key Takeaways - Benzinga
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Kura Oncology (KURA) Set to Release Q4 Earnings - GuruFocus
A Glimpse of Kura Oncology's Earnings Potential - Benzinga
Kura Oncology Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):